drugset / Trial / NCT06401707

PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest

NCT06401707

Phase 2 Recruiting 52 enrolled University of California, San Francisco
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. The investigators are proposing a pilot randomized placebo-controlled clinical trial to evaluate the safety and feasibility of perampanel use for post-cardiac arrest status epilepticus (PCARSE) prevention after cardiac arrest.

Timeline

Start
2024-05-20
Primary completion
2026-05-20
Completion
2026-10-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Perampanel Small molecule 8 mg Oral

Indications